anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to a medical information card that is in the form of a compact disk that has similar dimensions to a credit card. This compact disk is stored in a plastic sheath. An optional medical information sheet can be inserted into the plastic sheath adjacent to the medical information card so that a person inserting the medical information card into a computer will know whether a set of information stored on that card matches with a set of information stored on the sheet. Both the medical information card and the medical information sheet can have a digital picture of the user so that medical practitioners do not mix information relating to one user with information relating to another user. There is also a process for creating this medical information card. Essentially, the process includes the steps of presenting an application for a medical information card over a communication network, receiving medical and personal information from a user over that communication network, copying that information to a compact disk, and mailing the compact disk to the user. In a second embodiment of the process, the user can be presented with a paper-based application, wherein the user can then complete the application and then mail this application onto a receiving house where the information is eventually entered into a computer and then ultimately stored on a miniature compact disk.
Reproductive studies in animals were performed in mice, rats, and two strains of rabbits. Occasional anomalies (reduction of tarsals, tibia, metatarsals, malrotated limbs, gastroschisis, malformed skull, and microphthalmia) were seen in drug-treated rabbits without relationship to dosage. Although all of these anomalies were not present in the concurrent control group, they have been reported to occur randomly in historical controls. At doses of 40 mg/kg and higher, there was evidence of fetal resorption and increased fetal loss in rabbits which was not seen at lower doses.  
  
The clinical significance of the above findings is not known. However, an increased risk of congenital malformations associated with the use of minor tranquilizers (chlordiazepoxide, diazepam, and meprobamate) during the first trimester of pregnancy has been suggested in several studies. Because the use of these drugs is rarely a matter of urgency, the use of lorazepam during this period should be avoided. The possibility that a woman of childbearing potential may be pregnant at the time of institution of therapy should be considered. Patients should be advised that if they become pregnant, they should communicate with their physician about the desirability of discontinuing the drug.  
  
In humans, blood levels obtained from umbilical cord blood indicate placental transfer of lorazepam and lorazepam glucuronide. Infants of mothers who ingested benzodiazepines for several weeks or more preceding delivery have been reported to have withdrawal symptoms during the postnatal period. Symptoms such as hypoactivity, hypotonia, hypothermia, respiratory depression, apnea, feeding problems, and impaired metabolic response to cold stress have been reported in neonates born of mothers who have received benzodiazepines during the late phase of pregnancy or at delivery.
The invention discloses a targeted growth factor for promoting reconstruction of scar endometrium of an infertile woman and application thereof. The collagen targeting basic fibroblast growth factor is a protein formed by fusing a basic fibroblast growth factor and a collagen binding region. Experiments prove that: after collagen targeting basic fibroblast growth factor treatment, the menstrual blood volume, the thickness of the endometrium and the area of the scar endometrium of the infertility patient are all improved. Histological studies showed a significant increase in vascular density. 3 patients reached pregnancy at 20 weeks gestation. 1 patient delivered a healthy infant. The invention utilizes collagen targeted basic fibroblast growth factor to be injected into endometrium in multiple points, thereby improving the angiogenesis and proliferation capacity of endometrium and increasing the continuous pregnancy rate.
Tumor necrosis factor (TNF) induces systemic inflammatory response syndrome (SIRS), and severe SIRS can serve as a model for studying animal death caused by organ failure. Through strategic cecectomy, we demonstrate that necroptosis in the cecum initiates the death process in TNF-treated mice, but it is not the direct cause of death. Instead, we show that it is the cardiac dysfunction downstream of cecum damage that ultimately leads to the death of TNF-treated mice. By in vivo and ex vivo physiological analyses, we reveal that TNF and the damage-associated molecular patterns (DAMPs) released from necroptotic cecal cells jointly target cardiac endothelial cells, triggering caspase-8 activation and subsequent cardiac endothelial damage. Cardiac endothelial damage is a primary cause of the deterioration of diastolic function in the heart of TNF-treated mice. Our research provides insights into the pathophysiological process of TNF-induced lethality.
After rotator cuff injuries, uncontrolled inflammation hinders tendon-bone junction regeneration and induces scar formation in situ. Therefore, precisely controlling inflammation could be a solution to accelerate tendon-bone junction regeneration. In this study, we synthesized a peptide-metal ion complex hydrogel with thermosensitive capability that can be used as a hydrogel chemical regulator. By the coordination complex between Mg2+ and BMP-12, the free and coordinated Mg2+ can be programmability released from the hydrogel. The fast release of free Mg2+ can prevent inflammation at the early stage of injuries, according to the results of RT-qPCR and immunofluorescence staining. Then, the coordinated Mg2+ was slowly released from the hydrogel and provided an anti-inflammatory environment for tendon-bone junction regeneration in the long term. Finally, the hydrogel demonstrated enhanced therapeutic effects in a rat rotator cuff tear model. Overall, the Mg2+/BMP-12 peptide-metal ion complex-based hydrogel effectively addresses the regenerative requirements of the tendon-bone junction across various stages by graded modulating inflammation.
1430217 Blood substitute BIOTESTSERUM-INSTITUT GmbH 3 Oct 1973 [3 Oct 1972] 46157/73 Heading ASB Hepatitis-proof, storage-stable, infusible haemoglobin solution which has a stable 2, 3- diphosphoglycerate level is prepared by (a) treating human erythrocytes in dilute solution with beta-propiolactone, (b) washing the product with a neutral or weakly alkaline solution to remove excess beta-propiolactone and its reaction products, (c) haemolysing the erythrocytes by stirring them into distilled water or a physiologically acceptable electrolyte solution, (d) reducing the pH and potassium content of the haemolysate and precipitating the stromalipids by treating the haemolysate with a cation exchange resin in the H<+> form, (e) removing the resin and the precipitated stroma mass by centrifuge, (f) adding substances to regulate isotonicity and pH and optionally ferrohaemoglobin and (g) filtering the product under sterile conditions. The solution used to wash the erythrocytes may be sodium chloride or sodium bicarbonate solution. The cation-exchange resin may be a polystyrene sulphonate. The isotonicity may be adjusted by addition of glucose, sodium acetate or sodium bicarbonate. The pH may be adjusted by addition of sodium hydroxide. The sterile filtration may be through a cellulose asbestos filter or cellulose acetate disc. The solution may be concentrated before its isotonicity is adjusted by freezing it and collecting the haemoglobin-rich melt which runs off the frozen body. The product may be used as a blood substitute, particularly in cases of shock.
The invention provides a method and system for automatically tracking and managing inventory of surgical tools in an operating room. Embodiments described herein provide various examples of automatically processing surgical video to detect surgical tools and tool-related events and extract surgical tool usage information. In one aspect, a method for automatically detecting new surgical tool occupancy during a recorded surgical procedure is disclosed. The method may begin by receiving a surgical procedure video and then segmenting the surgical video into a sequence of video frames. Next, for each sequence of video frames, the video frames are processed to detect one or more surgical tools and one or more surgical tool occupancies associated with the detected surgical tools. If a surgical tool occupancy is detected in the sequence of video frames, the method then determines whether the detected surgical tool associated with the detected surgical tool occupancy is associated with a previously identified surgical tool occupancy. If not, the method identifies the detected surgical tool occupancy as a new surgical tool occupancy.
Individually titrate CONZIP by 100 mg every five days to a dose that provides adequate analgesia and minimizes adverse reactions. The maximum daily dose of CONZIP is 300 mg per day.

Continually reevaluate patients receiving CONZIP to assess the maintenance of pain control, signs and symptoms of opioid withdrawal, and other adverse reactions, as well as to reassess for the development of addiction, abuse, or misuse [see Warnings and Precautions (5.1, 5.18)]. Frequent communication is important among the prescriber, other members of the healthcare team, the patient, and the caregiver/family during periods of changing analgesic requirements, including initial titration. During use of opioid therapy for an extended period of time, periodically reassess the continued need for the use of opioid analgesics.

Patients who experience breakthrough pain may require a dosage adjustment of CONZIP or may need rescue medication with an appropriate dose of an immediate-release analgesic. If the level of pain increases after dosage stabilization, attempt to identify the source of increased pain before increasing the CONZIP dosage.

If the level of pain increases after dosage stabilization, attempt to identify the source of increased pain before increasing the CONZIP dosage. If after increasing the dosage, unacceptable opioid-related adverse reactions are observed (including an increase in pain after a dosage increase), consider reducing the dosage [see Warnings and Precautions (5)]. Adjust the dosage to obtain an appropriate balance between management of pain and opioid-related adverse reactions.
BACKGROUND: This study is the first to summarize the evidence on how the use of anti-inflammatory drugs during acute pain has an impact on the development of chronic pain.
METHODS: Randomized controlled trials retrieved from nine databases included anti-inflammatory drugs (NSAIDs or steroids) versus non-anti-inflammatory drugs in patients with acute pain and reported the incidence of chronic pain. No specified date, age, sex, or language restrictions. Subgroup analyses were performed according to pain classification, follow-up time, and medication. The GRADE method was used to evaluate quality of evidence.
RESULTS: A total of 29 trials (5220 patients) were included. Steroids or NSAIDs did not reduce the incidence of chronic nociceptive pain. Steroid use in acute phase significantly reduced the incidence of chronic neuropathic pain. In subgroup analysis, benefits were observed for methylprednisolone and dexamethasone, with some adverse effects. Steroids or NSAIDs were statistically significant in reducing pain intensity over 1 year, but the effect size was too small, and whether the long-term effect is clinically relevant needs to be further studied.
CONCLUSION: Quality of the evidence was low to moderate. No drug can be recommended to prevent chronic nociceptive pain. Injections of steroids (methylprednisolone or dexamethasone) during the acute phase reduce the incidence of chronic neuropathic pain, but most included studies also used local anesthetics. The results are indirect and need to be interpreted with caution. The pooled data effect sizes for pain intensity were small, so the clinical relevance was unclear. Study registration PROSPERO (CRD42022367030).
PROBLEM TO BE SOLVED: To obtain the subject composition capable of being rapidly absorbed to express a hypoglycemic action without being affected by foods by including a specific active ingredient and a low substituted hydroxypropylcellulose as a disintegrating agent. SOLUTION: This tablet composition comprises (A) N-(trans-4- isopropylcyclohexanecarbonyl)-D-phenylalanine of the formula and (B) a low substituted hydroxypropylcellullose. The ingredient B is preferably compounded in an amount of 5-40wt.%, and (C) a vehicle (e.g. lactose) and (D) hydroxypropylcellulose as a binder are preferably further compounded. The ingredient A and the components C and D are compounded e.g. in amounts of about 5-50%, 10-90% and 0.1-5%, respectively.
Systems, methods and computer program products for classifying documents are presented. Systems, methods and computer program products for analyzing documents, e.g., associated with legal discovery are also presented. Systems, methods and computer program products for cleaning up data are also presented. Systems, methods and computer program products for verifying an association of an invoice with an entity are also presented. Systems, methods and computer program products for managing medical records are presented. Systems, methods and computer program products for face recognition are presented.
The invention relates to a polypeptide capable of binding PD1, which is characterized by comprising 3 complementarity determining regions CDR1-3, the sequence of CDR1 is or comprises one of the sequences shown in SEQ ID NO. 1-17, the sequence of CDR2 is or comprises one of the sequences shown in SEQ ID NO. 18-34, and the sequence of CDR3 is or comprises one of the sequences shown in SEQ ID NO. 35-58. The invention aims at the polypeptide of PD1 to carry out nano antibody drug development and diagnostic kit development, and a nano antibody VHH specifically combined with PD1 is screened by preparing PD1 protein, immune alpaca, platform technology for displaying nano monoclonal antibody by using phage library and the like, and a CDR sequence of the nano antibody VHH is identified. The invention provides a potential nano-antibody new drug for clinical treatment of tumors and infectious diseases.
Patients randomized to receive 800 mg Imatinib were to receive 400 mg twice daily (b.i.d.) oral administration, in the morning and the evening. All patients received the assigned dose starting on Day 0 (Visit 3). The dose of Imatinib could be interrupted or reduced based on guidelines defined in protocol.
Trastuzumab (Herceptin®) tx will be administered weekly, together with one of the 2 weekly doses of Paclitaxel to Her-2/neu Positive patients. The 1st dose will be 4mg/kg given IV over 90 minutes. Weekly doses will b given at a dose of 2 17mg/kg/week IV over 30 minutes. The Tx with Trastuzumab will continue weekly after the completion of the radiation tx until surgery \& thereafter as per std of care up to 1 yr post surgery.Paclitaxel 30 mg/m2 twice per week given IV over 1 hour. Tx will be administered on a Monday/Thursday or Tuesday/Friday schedule.The radiation treatment will start within 1 week from the first dose of paclitaxel and trastuzumab.
Control area: In control area, the V.H.W. and supervisor records weight of all under 5 children. They also collect data related to birth, deaths and verbal autopsy.
An adenovirus, including adenoviral capsid proteins, and a replication-defective adenoviral vector that includes a 5" retroviral LTR nucleic acid sequence, a 3" retroviral LTR nucleic acid sequence, a nucleic acid sequence encoding a portion of a retroviral envelope protein adjacent to either the 5" LTR or the 3" LTR nucleic acid sequence, a retroviral packaging sequence and a nucleic acid sequence encoding a transgene located between the 5" LTR and the 3" LTR is provided. Host cells infected with this adenovirus are also provided. An adenoviral vector is provided that includes an adenoviral polynucleotide sequence comprising a nucleic acid encoding a transgene, a retroviral packaging signal, a 5" and a 3" retroviral LTR, and a portion of a retroviral envelope polypeptide, wherein the adenoviral polynucleotide sequence does not encode one or more of E1, E3 or E4. A method for transforming a cell is also provided using a virus or a vector of the invention, as is a method for introducing a transgene into a cell that is not able to produce viral particles with a single viral vector. A method is also provided for preventing or treating disorder in a subject using the adenoviral vectors of the invention. A pharmaceutical composition is also provided that includes an adenoviral vector of the invention and a pharmaceutically acceptable carrier.
BACKGROUND: Rheumatoid arthritis (RA) is a common acute inflammatory autoimmune connective tissue arthropathy. The genetic studies, tissue analyses, experimental animal models, and clinical investigations have confirmed that stromal tissue damage and pathology driven by RA mounts the chronic inflammation and dysregulated immune events.
METHODS: We developed methotrexate (MTX)-loaded lipid-polymer hybrid nanoparticles (MTX-LPHNPs) and aceclofenac (ACE)-loaded nanostructured lipid carriers (ACE-NLCs) for the efficient co-delivery of MTX and ACE via intravenous and transdermal routes, respectively. Bio-assays were performed using ex-vivo skin permeation and transport, macrophage model of inflammation (MMI) (LPS-stimulated THP-1 macrophages), Wistar rats with experimental RA (induction of arthritis with Complete Freund's adjuvant; CFA and BCG), and programmed death of RA affected cells. In addition, gene transcription profiling and serum estimation of inflammatory, signaling, and cell death markers were performed on the blood samples collected from patients with RA.
RESULTS: Higher permeation of ACE-NLCs/CE across skin layers confirming the greater "therapeutic index" of ACE. The systemic delivery of MTX-loaded LPHNPs via the parenteral (intravenous) route is shown to modulate the RA-induced inflammation and other immune events. The regulated immunological and signaling pathway(s) influence the immunological axis to program the death of inflamed cells in the MMI and the animals with the experimental RA. Our data suggested the CD40-mediated and Akt1 controlled cell death along with the inhibited autophagy in vitro. Moreover, the ex vivo gene transcription profiling in drug-treated PBMCs and serum analysis of immune/signalling markers confirmed the therapeutic role co-delivery of drug nanoparticles to treat RA. The animals with experimental RA receiving drug treatment were shown to regain the structure of paw bones and joints similar to the control and were comparable with the market formulations.
CONCLUSION: Our findings confirmed the use of co-delivery of drug nanoformulations as the "combination drug regimen" to treat RA.
INTRODUCTION: Obesity is an increasing public health concern worldwide and can lead to more complications in pregnancy and childbirth. Women with obesity more often require induction of labor for various indications. The aim of this study is to assess which method of induction of labor is safest and most effective in women with obesity.
MATERIAL AND METHODS: This is a secondary analysis of two randomized controlled trials about induction of labor. Women with a term singleton pregnancy in cephalic presentation, an unfavorable cervix, intact membranes and without a previous cesarean section were randomly allocated to cervical priming with a Foley catheter or vaginal prostaglandin-E2-gel (PROBAAT-I) or a Foley catheter or oral misoprostol (PROBAAT-II). The inclusion and exclusion criteria for the studies were identical. Induction methods were compared in women with obesity (body mass index ≥30.0). Main outcomes were cesarean section and postpartum hemorrhage (blood loss >1000 mL).
RESULTS: A total of 2664 women, were included in the trials, 517 of whom were obese: 254 women with obesity received a Foley catheter, 176 oral misoprostol and 87 prostaglandin E2 (PGE2). A cesarean section was performed in 29.1% of women allocated to Foley vs 22.2% in the misoprostol and 23.0% in the PGE2 groups. Comparisons between groups revealed no statistically significant differences: the relative risk [RR] was 1.31 (95% confidence interval [CI] 0.94-1.84) in the Foley vs misoprostol group and 1.27 (95% CI 0.83-1.95) in the Foley vs PGE2 group. The rates of postpartum hemorrhage were comparable (10.6%, 11.4% and 6.9%, respectively; P = 0.512). In women with obesity, more often a switch to another method occurred in the Foley group, (20.1% vs 6.3% in misoprostol vs 1.1% in the PGE2 group; P < 0.001). The risk of a failed Foley placement was higher in women with obesity than in women without obesity (8.3% vs 3.2%; adjusted odds ratio 3.12, 95% CI 1.65-5.90).
CONCLUSIONS: In women with obesity we found a nonsignificant trend towards an increased rate of cesarean sections in the group induced with a Foley catheter compared to oral misoprostol; however, the study lacked power for this subgroup analysis. The finding of a higher risk of failed placement of a Foley catheter in women with obesity can be used in shared decision making.
1. A pharmaceutical remedy characterised in that it contains at least one compound selected from a group consisting of 4,5-dihydroxy-2-cyclopenten-1-one represented by the following formula [I] and an optically active substance and a salt thereof as an effective component, wherein said pharmaceutical remedy is selected from a group consisting of antirheumatic agent, rheumatism preventor, resolvent, inflammation preventor, production factor tumour necrosis inhibitor, production factor tumour necrosis preventor, nitric monoxide production inhibitor, neovascularization inhibitor, carcinogenesis preventor, meliorative remedy in case of ischemic disorder of cerebrum, inducing remedy for Fas-antigen production, immunomodulating remedy and topoisomeraza inhibitor.   2. A pharmaceutical remedy according Claim 1, wherein said pharmaceutical remedy is immunomodulating remedy selected from a group consisting of production interleucine-10 enhancer, IgE production inhibitor, hyperperceptibility of slowed type inhibitor, lymphocyte proliferation inhibitor, and oedema inhibitor. 3. Food or beverage characterized in that it contains at least one compound is selected from a group consisting of 4,5-dihydroxy-2-cyclopenten-1-one represented by the formula [I] and an optically active substance and a salt thereof as effective component, wherein said food or beverage is selected from a group consisting of food or beverage for the improvement or prevention of rheumatism, for the improvement or prevention of inflammation, production factor tumour necrosis inhibiting, reinforcement of interleucine-10 production, nitric monoxide production inhibiting, Fas-antigen production inducing, for immunomodulating, IgE production inhibiting and topoisomeraza inhibiting.  .